Oddity Tech, the innovative company behind popular beauty brands like Il Makiage and SpoiledChild, is set to introduce its third brand, Methodiq. This new venture is a telehealth platform initially targeting skin conditions such as acne, hyperpigmentation, and eczema. With over 60 million users on its existing platform, Oddity sees a significant opportunity to expand its offerings. According to Oran Holtzman, the co-founder and CEO, many users are struggling with skin issues and often find current treatments inadequate. Methodiq aims to leverage the company’s expertise in beauty alongside cutting-edge technology to disrupt the medical care market for skin conditions.
Methodiq’s approach to dermatology integrates advanced tools, including AI-powered skin analysis and computer vision for tracking progress. Users engage with the platform through the Methodiq App by completing weekly check-ins, allowing for ongoing adjustments to their treatment plans based on real-time insights shared with assigned clinicians. However, it’s important to note that Methodiq does not accept insurance, reflecting a growing trend in direct-to-consumer healthcare services. This model empowers patients to take control of their skincare journeys while receiving tailored guidance from professionals.
At launch, Methodiq boasts an impressive lineup of 28 core products and over 100 personalized treatment options, blending prescription, over-the-counter, and cosmetic formulations. Some standout offerings include Clindalaq 305, a topical prescription combining clindamycin, tretinoin, and niacinamide, as well as Trazelaq 305 for severe acne and Spironolactone for oral treatment. The brand also introduces innovative makeup solutions specifically designed for acne-prone skin, such as SkinShield, a foundation developed by dermatologists, and SpotShield, a concealer enriched with beneficial ingredients like salicylic acid and niacinamide.
Oran Holtzman emphasizes that their mission goes beyond mere improvement of existing healthcare solutions; it’s about rethinking how the system operates. Tom Amsterdam, the CEO of Methodiq, echoes this sentiment, stating that they have collaborated closely with healthcare professionals to create a more patient-centered healthcare experience. By reconstructing the layers of healthcare, Methodiq seeks to provide more effective care with reduced obstacles, setting a new standard in the industry.
To promote Methodiq, Oddity has planned an extensive marketing campaign that will leverage both traditional and digital platforms, including billboards and advertisements in the New York City subway system. This campaign aims to enhance visibility and attract new users to the platform, especially those suffering from skin conditions who may feel underserved by existing solutions.
Oddity Tech’s growth trajectory remains strong, with a notable increase in net revenue in the second quarter of 2024, rising to $241 million from $193 million the previous year. The company has also adjusted its revenue forecast for the entire year, now expecting net revenue between $799 and $804 million. Furthermore, the adjusted diluted earnings per share are predicted to be between $2.06 and $2.09, indicating a robust financial outlook as Oddity prepares to expand its brand portfolio with the launch of a fourth brand next year.
